- Home
- CXE vs CGTX Comparison
CXE vs CGTX Comparison
Compare CXE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CXE | CGTX |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.1M | 94.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CXE | CGTX |
|---|---|---|
| Price | $3.70 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 53.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $52.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.38 | $0.22 |
| 52 Week High | $3.88 | $3.83 |
Technical Indicators
Market Signals| Indicator | CXE | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 40.94 |
| Support Level | $3.68 | $0.56 |
| Resistance Level | $3.76 | $0.87 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 36.84 | 42.91 |
Price Performance
Historical ComparisonAbout CXE MFS High Income Municipal Trust
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.